Paul Hockings, Senior Scientific Advisor at Antaros Medical, will be giving a short presentation at the 10th Kidney Disease Clinical Trialists (KDCT) Workshop later this week. This year’s KDCT Workshop is from April 10-11 at the Embassy of France in Washington D.C.
The KDCT Workshop is a specialized closed meeting for nephrologists, clinical trialists, principal investigators, and statisticians across academia, industrym and regulatory/health bodies such as the U.S Food & Drug Administration (FDA) and European Medicines Agency (EMA). The workshop aims to foster an exchange of ideas with the objective of improving kidney disease clinical trials.
Paul’s presentation will be part of the ‘AKI 2 – Gene Therapy’ session on Saturday April 11. It will focus on the importance of precision for measuring endpoints like total kidney volume (TKV) in trials with smaller patient populations, as is often the case with autosomal dominant polycystic kidney disease (ADPKD). Advanced magentic resonance imaging (MRI) methods for measuring TKV can detect changes with much greater precision than other methods, offering valuable insights and evidence into treatment effects. Paul will also discuss briefly what imaging can do beyond TKV in ADPKD trials, for example, detecting slowing kidney cyst growth through endpoints such as cyst number and size distribution or cyst surface area.